Skip to content

White House Plan to Cut Drug Prices Gets Shrugs From Investors

The Biden administration’s assertion Thursday that it can break the patents of certain high-price drugs could represent a significant challenge to the drug industry, but its practical implications appear limited, at least for now.

Continue reading this article with a Barron’s subscription.

View Options